MiRNA182 was found to be decreased in the initial stage of acute nerve injury, allowing for essential inflammatory reaction and increased SC migration by targeting fibroblast growth factor 9 (FGF9) and Neurotrimin (NTM) (76). The gene discussed is FGF9; the disease is injury.